CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗实体瘤：临床挑战与当前进展
英文原题：CAR T-Cell Therapy for Solid Tumors: Clinical Challenges and Current Advancements.
查看英文原题
CAR T-Cell Therapy for Solid Tumors: Clinical Challenges and Current Advancements.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR-T 细胞）疗法已经彻底改变了血液系统恶性肿瘤的治疗结局，但其向实体瘤的转化仍受限于安全性和有效性方面的障碍。恶性组织与正常组织之间的抗原重叠会导致靶向性、脱靶毒性，而免疫抑制性肿瘤微环境则限制了CAR-T 细胞的浸润、持久性和细胞毒性。局部区域治疗策略进一步旨在优化递送。本综述强调，要将CAR-T 细胞疗法成功整合到实体瘤患者的治疗中，需要改进抗原选择、严谨的试验设计以及多学科协作。
展开英文摘要原文
Chimeric antigen receptor (CAR T-cell) therapy has revolutionized outcomes in hematologic cancers, yet translation to solid tumors remains limited by safety and efficacy barriers. Antigen overlap between malignant and normal tissues leads to on-target, off-tumor toxicity, while the immunosuppressive tumor microenvironment restricts trafficking, persistence, and cytotoxicity.
Locoregional approaches further aim to optimize delivery. This review highlights that improved antigen selection, rigorous trial design, and multidisciplinary collaboration will be required to successfully integrate CAR T-cell therapy into the care of patients with solid tumors.
论文信息
- 作者
- Gutierrez A、Eil R
- 第一作者单位
- Department of Surgery, Division of General Surgery, School of Medicine, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239, USA.United States
- 通讯作者单位
- Department of Surgery, Division of Surgical Oncology, School of Medicine, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239, USA. Electronic address: EIL@OHSU.EDU.United States
- 文献类型
- 综述
- 期刊
- Surgical oncology clinics of North America2026 Apr
- 原文标识
- PubMed 41903985 · DOI 10.1016/j.soc.2025.10.001